e-learning
resources
Barcelona 2013
Wednesday, 11.09.2013
Growth factors at the crossroads of acute and chronic inflammation
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Collagen V activation and matrix extracellular remodeling mediated pulmonary fibrosis in experimental models of bleomycin and 3-5-di-tert-4-hidroxitoluene
D. Lopes, V. Martins, W. Teodoro, E. R. Parra, V. L. Capelozzi (São Paulo, Brazil)
Source:
Annual Congress 2013 –Growth factors at the crossroads of acute and chronic inflammation
Session:
Growth factors at the crossroads of acute and chronic inflammation
Session type:
Poster Discussion
Number:
4895
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Lopes, V. Martins, W. Teodoro, E. R. Parra, V. L. Capelozzi (São Paulo, Brazil). Collagen V activation and matrix extracellular remodeling mediated pulmonary fibrosis in experimental models of bleomycin and 3-5-di-tert-4-hidroxitoluene. Eur Respir J 2013; 42: Suppl. 57, 4895
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The new challenge of CTD-ILD: from basic science to clinical setting
Related content which might interest you:
Targeting the hedgehog/GLI pathway decreases bleomycin-induced lung fibrosis
Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung
Year: 2013
Collagen V overexpression correlates with IL-17+ cells in C57BL/6 mice pulmonary remodeling
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Metalloproteases gene expression and remodeling of lung parenchyma fibers during the progression of elastase induced emphysema
Source: International Congress 2014 – Mechanisms of COPD and inhalation injury
Year: 2014
Matrix metalloproteinase-2 is protective in bleomycin-induced pulmonary fibrosis
Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions
Year: 2015
A transient receptor potential melastin-2 deficiency significantly worsens the fibrotic response to bleomycin in mice
Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury
Year: 2013
Comparison of expression of napsin A and surfactant protein D in bleomycin-induced pulmonary fibrosis mouse model
Source: Annual Congress 2013 –Diffuse parenchymal lung disease I
Year: 2013
KCa3.1 channel inhibition prevents fibrotic responses in a human lung explant model
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015
Adventitial remodeling of experimental pulmonary hypertension induces myofibroblast-produced collagen V in a Th17-pathways-related manner
Source: International Congress 2016 – Pulmonary hypertension: novel insights
Year: 2016
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced idiopathic pulmonary fibrosis by regulation of extracellular matrix remodelling
Source: Annual Congress 2013 –Novel mechanisms in lung injury
Year: 2013
Resveratrol regulates ECM remodeling in lung fibrosis
Source: International Congress 2014 – New and old players in fibrotic lung disease
Year: 2014
Thymosin beta4 protects mice from bleomycin-induced damage in the lung
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Regulation of autophagy in amiodarone induced pulmonary fibrosis
Source: Annual Congress 2013 –The vulnerable patient and ageing cells
Year: 2013
Nintedanib inhibits fibroblast activation and ameliorates pulmonary and dermal fibrosis in models of systemic sclerosis (SSc)
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Specialized-proresolving mediators and trancriptomic signatures in bleomycin-induced lung fibrosis
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016
The immunomodulatory effect of protein S in pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
FGF-9 overexpression prevents pleural fibrosis induced by intra-pleural adenovirus injection in mice
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Interaction between mitochondrial ROS and ER stress on PHMG-induced pulmonary fibrosis
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
Silica-induced inflammasome activation
in vitro
and in rat lungs
Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013?
Year: 2013
Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013
Alveolar type II cells transplantation decrease fibrocyte migration in pulmonary fibrosis
Source: Annual Congress 2013 –Novel mechanisms in lung injury
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept